Results 41 to 50 of about 9,123 (152)

Physiology-based IVIVE predictions of tramadol from in vitro metabolism data [PDF]

, 2014
To predict the tramadol in vivo pharmacokinetics in adults by using in vitro metabolism data and an in vitro-in vivo extrapolation (IVIVE)-linked physiologically-based pharmacokinetic (PBPK) modeling and simulation approach (SimcypA (R)).
Allegaert, Karel, Annaert, Pieter, Boussery, Koen, Colin, Pieter, Cuyckens, Filip, Mannens, Geert, Snoeys, Jan, T'jollyn, Huybrecht, Van Bocxlaer, Jan, Van Peer, Achiel, Vermeulen, An   +10 more
core   +1 more source

Derivation of a health‐based guidance value for Δ8‐tetrahydrocannabinol (Δ8‐THC) and its occurrence in food

EFSA Journal, Volume 23, Issue 11, November 2025.
Abstract The European Food Safety Authority (EFSA) was asked to deliver a scientific opinion on the derivation of a health‐based guidance value (HBGV) for Δ8‐tetrahydrocannabinol (Δ8‐THC) in food with an assessment of the occurrence of Δ8‐THC and the co‐occurrence with Δ9‐THC in hemp and hemp‐derived products.
EFSA Panel on Contaminants in the Food Chain (CONTAM), Helle Katrine Knutsen, Agneta Åkesson, Vasileios Bampidis, Margherita Bignami, James Kevin Chipman, Gisela Degen, Antonio Hernández‐Jerez, Tim Hofer, Christer Hogstrand, Stefano Landi, Jean‐Charles Leblanc, Kyriaki Machera, Evangelia Ntzani, Isabelle P. Oswald, Guido Rychen, Salomon Sand, Katharina Vejdovszky, Barbara Viviani, Birgit Dusemund, Carlo Nebbia, Stefan Weigel, Claudia Cascio, Anna Christodoulidou, José Cortiñas Abrahantes, Bruno Dujardin, Andrea Gissi, Lydia Alarcón Asensio, Eleni Gkimprixi, Tuuli Tauriainen, Laurent Bodin   +30 more
wiley   +1 more source

Genetic polymorphisms of CYP3A5, CHRM2, and ZNF498 and their association with epilepsy susceptibility: a pharmacogenetic and case–control study

Pharmacogenomics and Personalized Medicine, 2019
Laith N AL-Eitan1,2, Islam M Al-Dalalah1, Mohamed M Mustafa3, Mansour A Alghamdi4, Afrah K Elshammari5, Wael H Khreisat5, Mohammed N Al-Quasmi6, Hanan A Aljamal1 1Department of Applied Biological Sciences, Jordan University of Science and Technology ...
AL-Eitan LN, Al-Dalalah IM, Mustafa MM, Alghamdi MA, Elshammari AK, Khreisat WH, Al-Quasmi MN, Aljamal HA   +7 more
doaj  

Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients [PDF]

, 2018
Objective: To measure the in vivo variations of CYP3A activity induced by anti-HIV drugs in human immunodeficiency virus (HIV)1-positive patients. Methods: A low oral dose of midazolam (MID) (0.075mg) was given to the patients and the 30-min total 1-OH ...
Baumann, Pierre, Buclin, Thierry, Decosterd, Laurent, Eap, Chin, Fellay, Jacques, Golay, Kerry, Marzolini, Catia, Telenti, Amalio   +7 more
core  

Effect of Mild to Moderate Hepatic Impairment on Valemetostat Pharmacokinetics: An Open‐Label, Phase I Study

Clinical Pharmacology in Drug Development, Volume 14, Issue 8, Page 631-641, August 2025.
Abstract Valemetostat tosylate (valemetostat) is a dual inhibitor of enhancer of zeste homolog (EZH) 2 and EZH1, approved in Japan for the treatment of relapsed/refractory peripheral T‐cell lymphoma and adult T‐cell leukemia/lymphoma. This Phase I, open‐label study evaluated the pharmacokinetics and safety of a single 50‐mg oral dose of valemetostat in
Masaya Tachibana, Thuy Vu Craveiro, Thomas C. Marbury, Samuel Oberstein, George J. Atiee, Ben Tao, Takako Shimizu, Yvonne Lau, Malaz A. Abutarif   +8 more
wiley   +1 more source

Expression profiles of a drug metabolizing enzyme CYP3A62 mRNA in the intestine of rats [PDF]

, 2007
The purpose of this study was to examine the expression profiles of a drug metabolizing enzyme cytochrome P450 (CYP) 3A62 mRNA in the intestine and liver of normal male Wistar rats, and its regional differences in the intestinal tract. Nine-week-old male
Horibe, Sayo, Kishi, Hisato, Kitada, Noriaki, Ohnishi, Noriaki, Takara, Kohji, Yokoyama, Teruyoshi, Yoshikawa, Eri   +6 more
core  

Population Genetic-Based Pharmacokinetic Modeling of Methadone and its Relationship with the QTc Interval in Opioid-Dependent Patients. [PDF]

, 2016
Methadone is a μ-opioid agonist widely used for the treatment of pain, and for detoxification or maintenance treatment in opioid addiction. It has been shown to exhibit large pharmacokinetic variability and concentration-QTc relationships.
Eap, C.B., Guidi, M.
core   +1 more source

Drug Exposure in Chronic Kidney Disease: It Is Not Just About the Glomerular Filtration Rate

Fundamental &Clinical Pharmacology, Volume 39, Issue 4, Page 1-10, August 2025.
ABSTRACT Chronic kidney disease (CKD) affects over 10% of the world's population and is associated with high morbidity and mortality rates. The management of CKD is complex; CKD alters drug pharmacokinetics and pharmacodynamics and further complicates therapeutic strategies regimens.
Sophie Liabeuf, Jessica Berdougo‐Tritz, Lucie Augey, Aïcha Mbarek, Michel Jadoul, Gilbert Deray, Ziad A. Massy   +6 more
wiley   +1 more source

CYP3A-fenotype hos leddgiktpasienter i relasjon til inflammasjonsstatus og behandling med biologiske DMARDs [PDF]

, 2015
Bakgrunn: Enzymer tilhørende cytokrom P-450 3A (CYP3A)-subfamilien er de viktigste i metabolisme av legemidler. Systemisk inflammasjon er foreslått som en faktor til den store interindividuelle variabiliteten i CYP3A-fenotype, og 4β-hydroksykolesterol ...
Wollmann, Birgit Malene Tovik
core  

Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: Recent developments and ethnic considerations [PDF]

, 2016
Introduction: Tacrolimus (Tac) is effective in preventing acute rejection but has considerable toxicity and inter-individual variability in pharmacokinetics and pharmacodynamics.
Andrews, L.M. (Louise), Gelder, T. (Teun) van, Hesselink, D.A. (Dennis), Schaik, R.H.N. (Ron) van, Shi, Y.Y. (Yunjing), Tang, J.T. (Jiang-Tao), Wang, L.L. (Lanlan)   +6 more
core   +3 more sources